In cancer, for example, statins such as lovastatin and simvastatin disrupt EGFR- or IGF1R-containing lipid rafts, and enhance the efficacy of TKIs in prostate, breast, and lung cancer models [79]. This evidence concerns the gene EGFR and lung cancer.